IBM Set For Growth In 2017; Morgan Stanley Trims Target To $179
Katy Huberty of Morgan Stanley maintains her Overweight rating on International Business Machines Corp. (NYSE: IBM) shares, as she believes that the company is set for growth next year, driven by Strategic Imperatives, coupled with free cash flow ahead of earnings and PTI margin pressures receding.
The analyst also pointed out that the CFO commentary on 2017 indicates earnings growth despite continued investments.
IBM’s revenue beat expectations for the third quarter in a row with organic revenue decline improving from the second quarter. PTI margin decline also improved (-1.6 point year-over-year versus a -5 point average prior three quarters) as restructuring savings begin to flow through.
On the flip side, though PTI margin trends improved, gross margin dropped 205bps year-over-year, slightly worse than the prior three quarters.
“We attribute the gross margin decline to 1) shifting some software revenues to IP Income as IBM increasingly licenses technology in non-Strategic businesses, and 2) continued pressure in Cognitive Computing margins as the company invests for future growth,” Huberty wrote in a note.
“Both trends are likely to continue but mix shift toward higher margin Software and Strategic Imperatives revenue combined with improving GBS and cloud margins allows for modest gross margin expansion next year, in our view,” Huberty continued.
In addition, the analyst believes IBM is on track for 2017 growth, with currency impact neutralizing and momentum driven by 42 percent estimated revenue contribution from Strategic Imperatives and Global Technology Services (GTS).
Furthermore, margins are expected to improve in several areas of services and cloud, while further restructuring savings could be reinvested in growth areas.
‘We continue to see modest EPS growth in CY17 as mix shift to software and restructuring savings offset aggressive investments in growth areas like Cognitive and Cloud. Our CY17 EPS of $14 is unchanged,” Huberty noted.
However, the analyst modestly cut the price target to $179 from $182. The new target continues to assume 12.5x P/FCF on CY17 FCF, which the analyst lowered slightly to $14.33 from $14.57.
“This is in-line with the low-end of software and services peers (Oracle Corporation (NYSE: ORCL)), however, as Watson contribution increases we see the potential IBM achieves a multiple closer to Microsoft Corporation (NASDAQ: MSFT), or 15.5x bull case FCF of $14.75,” Huberty added.
Shares of IBM closed Monday’s trading at $154.77. In the pre-market hours, the stock fell 2.57 percent to $150.80.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email firstname.lastname@example.org with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Latest Ratings for IBM
|Jan 2017||Guggenheim||Initiates Coverage On||Neutral|
|Nov 2016||Bank of America||Upgrades||Neutral||Buy|
|Oct 2016||Goldman Sachs||Maintains||Neutral|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.